Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure
First Claim
1. A method for the treatment of a patient having an asymptomatic (occult) heart failure corresponding to the International Small Animal Cardiac Health Council (ISACHC) guidelines for Class I asymptomatic heart failure comprising administering a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
40 Citations
18 Claims
- 1. A method for the treatment of a patient having an asymptomatic (occult) heart failure corresponding to the International Small Animal Cardiac Health Council (ISACHC) guidelines for Class I asymptomatic heart failure comprising administering a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof.
- 10. A method for prolongation of the time until onset of clinical symptoms in a patient having an asymptomatic (occult) heart failure corresponding to the International Small Animal Cardiac Health Council (ISACHC) guidelines for Class I asymptomatic heart failure comprising administering a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof.
Specification